Description

Elamipretide (MTP-131) is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C32H49N9O5—Am J Transl Res. 2020 Sep 15;12(9):5080-5094.|Brain Res. 2024 Mar 21:148882.|Cell Commun Signal. 2024 Jan 10;22(1):26.|Hum Mol Genet. 2019 Apr 1;28(7):1100-1116. |JCI Insight. 2021 Dec 7;e152102.|Research Square Preprint. 2022 Jul.|Sci Adv. 2022 Apr 8;8(14):eabl4370.|Biomed Pharmacother. 2024 Jan 9:171:116110.|Cryobiology. 2020 Aug;95:138-142.|Hum Exp Toxicol. 2020 May;39(5):673-682.|Research Square Preprint. 2020 Aug.-[1]Zhao W, et al., Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019 Nov 20;16(1):230.|[2]Sabbah HN,et al., Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016 Feb;9(2):e002206.–736992-21-5–639.79–99.89–O=C(N)[C@H](CC1=CC=CC=C1)NC([C@H](CCCCN)NC([C@H](CC2=C(C)C=C(C=C2C)O)NC([C@@H](CCCNC(N)=N)N)=O)=O)=O–Inflammation/Immunology; Neurological Disease; Cardiovascular Disease–DMSO : ≥ 29 mg/mL–Mitochondrial Metabolism—-Metabolic Enzyme/Protease–Peptides